Printer Friendly

The role of neurotransmitters in IBS pathophysiology: a literature review.

Objective: To determine if neurotransmitters have relevance in the pathology of irritable bowel syndrome (IBS).

Review methods: Electronic searches of literature from PUBMED, MEDLINE and EBSCO in October and November 2006 using the terms IBS, neurotransmitters, serotonin, CCK, mast cell, 5-HT, substance P. Some of the articles were only published in abstract form.

Review: Clinical studies performed on colon tissue of rodents and humans and trials on the effects of serotonin (5-HT) antagonists in IBS generally and rectal hypersensitivity are included. Two trials on cholecystokinin (CCK) were reviewed with regards to their impact in IBS. The most extensively researched was 5-HT often with a view to patenting medications or establishing new approaches to treatment of IBS. These have been invaluable in understanding the role of hormones in the disorder. IBS occurs more commonly in women and three studies recorded that women have an increased rectal sensitivity to distension. Substance P, a neuropeptide, has been found in higher levels in the tissue of IBS patients in two studies and may have a role in the pain of the disorder. Two studies observed the impact of extreme stresses such as sexual abuse, depression and explosive noise on colon motility. These stresses altered colon motility and rectal threshold. Trials on 5-HT antagonists and other IBS drug therapies were researched for appropriateness to the topic. Of the 29 studies on neurotransmitters, 24 were on humans or human tissue. Reviews of other research have also been included. The summary of research is included in Table 1.

Trials of herbal medicines on IBS were researched for general reference but not included. The emphasis of these studies is to establish efficacy rather than the pharmacodynamic relationship to neurotransmitter release in IBS. Symptoms were evaluated as a reduction in pain, discomfort and intestinal motility.

Conclusions: The impact of 5-HT is of significance in IBS. Trials on CCK are few, and of the two cited one had minor relevance to IBS symptoms. Many of the clinical trials are on the significance of 5HT, propelled by pharmaceutical companies to find a patented drug for treatment. Whilst the 5-HT antagonists do have positive outcomes against placebo (ie: reduced rectosigmoid sensitivity, reduced bloating, reduced colon motility) the drugs tested had insignificant impact on the pain of IBS. Studies into mast cells have elucidated the impact of local neuropeptides on the pain mechanisms in IBS and this may be an area of further study. Prior inflammation may have a role is establishing alterations in immunoreactivity in the colorectal mucosa.


IBS is a chronic disorder of recurring symptoms including abdominal pain, feeling of discomfort and bloating with altered bowel habits. It can be divided in to IBS-D (diarrhoea dominant), IBS-C (constipation dominant) or alternating D and C and further in IBS-PI (post infective). Patients are categorised according to their symptoms and the absence of other organic disease of the colon. IBS is not well understood and many factors have been attributed to its occurrence, such as food allergies/intolerance, stress, genetic disposition, depression, central nervous system (CNS) disturbance and recently altered neurotransmitter release (Talley 2005, Santos 2005). IBS can occur following gastroenteritis or other inflammation (Talley 2005). Colon hypersensitivity is a common symptom of IBS particularly in IBS-D (Chang 2006, Xiao 2004). Research has suggested that food intolerances and ultimately mast cell mediators may be responsible for such hyperalgesia (Santos 2005).

Originally considered a functional disorder, research into the role of neurotransmitters indicates a neurological origin (Aggarwal 2006). Ninety five percent of total body 5-HT is located in the GIT (Moura 2005). It is secreted by the enterochromaffin cells of the microvilli and it promotes peristalsis in the GIT. Patients with IBSD have been found to have excess amounts of 5-HT (Pimentel 2004). Due to these findings research into 5-HT antagonists has explored drug therapies that attempt to remedy this excess. The development of 5-HT antagonists has been difficult due to toxicity of the drugs. They have proven to be only modestly effective over placebo and have little in the way of long term safety data (Talley 2005, Moura 2005). Most of the trials are of small number, over a period of weeks. They are invaluable in terms of the information they reveal regarding the pathology of IBS. One doctor warns that these medications should only be used when required and not long term (Moura 2005). The findings that the disorder is greatly affected by hormones and neurotransmitters gives a therapist a broader therapeutic range of treatment options.

Stress and food intolerances have been generally implicated in IBS. There have been concepts elucidated through research which suggest that stress and food intolerances may cause alterations in local gut hormones and the sensitising of mast cells. Allergenic reaction causes mast cells to overexcite enteric nerve endings (Guilarte 2006, Bischoff 2004) and this could explain visceral hypersensitivity, a symptom that occurs commonly in IBS-D particularly in women.

Hormones implicated in IBS

Serotonin 5-HT

Serotonin is a gut hormone implicated in the pathology of IBS. The microvilli cells of the GIT secrete 5-HT. The activity of 5-HT is concentrated in the GIT (95%) where it initiates peristalsis and induces contraction of the internal anal sphincter (Mulak 2006).

Postprandial 5-HT is elevated in IBS-D patients (Pimentel 2004) and pain in IBS correlates with peak plasma concentrations of 5-HT (Hicks 2002). It has not been established why a patient would have more 5-HT receptors and 5-HT activity than another. It may be linked to a prior gastrointestinal infection. In a study of rectal mucosal enteroendocrine cells (EC) post enteritis infection, Spiller (2000) noted that 5-HT receptor containing ECs were increased after the first biopsy at 3 weeks. This increase in 5-HT is part of a primitive protective cleansing mechanism which induces vomiting and diarrhea, thereby clearing infective pathogens by copious secretions and increased motility. In the same study 5-HT receptors remained in excess in some cases for up to one year after the initial acute episode passed. Most of the studies of IBS-D showed an increase in 5-HT activity and those improved with 5-HT antagonists.

Serotonin (5-HT) treatment in IBS

Allopathic treatment of visceral pain includes smooth muscle relaxants which are effective in IBS-D and abdominal pain but not IBS-C (Talley 2005). Tri-cyclic antidepressants at a low dose have been used for IBS but tend to be constipating (Talley 2005).

Trials on 5-HT antagonists are showing relatively moderate success in reducing bloating and reducing colon motility. In a 3 week preliminary drug study by Tack et al (2006), SSRI Citalopram[R] was effective in reducing bloating, abdominal pain and quality of life compared with placebo (Tack 2006). Mulak (2006), in a preliminary drug study, confirmed that sumatripin 5-HT agonist was active in reducing anal recto tension indicating that serotonin receptivity has a role in the regulation of rectal tone. The 5-HT antagonist alosetron was effective in inhibiting motor activity in the small and large bowel (Bush 2001). In particular this study confirmed that there are gender specific receptor sites for 5-HT antagonists in the large bowel. Females had more 5-HT receptors in the large bowel than males. Even though this study was on rodents, bowel hypersensitivity has been confirmed by Xiao (2004) and Chang (2006) with the use of inflatable distension balloon tests. The presence of more 5-HT receptors in the colorectal area gives some explanation as to why women suffer with IBS-D more than men. It is via this mechanism in particular that more trials are being conducted in humans rather than the preliminary animal testing.

Receptors for 5-HT are species specific. Many studies into drug efficacy have been carried out on animal tissue and then in patient tolerability of a particular 5-HT antagonist. Borman (2002) isolated a human specific receptor for 5-HT, 5-HT 2B which is specifically excitatory in humans and not found in animals. The receptors 5-HT 3 and 5-HT 4 are excitatory in guinea pigs, 5-HT 3 and 5-HT 1 receptors are excitatory in rats, where human 5-HT 2B receptors are highly reactive, more than 1000 times greater than other receptors. This will alter the approach of drug development and treatment by targeting human specific receptors. Many other studies are on animal tissue and may not be appropriate references because of interspecies variations.

Herbal treatment employs nervines, antispasmodics, carminatives and sedatives to deal with the symptoms of IBS (Braun 2005, Bian 2006, Bundy 2004).


CCK has a role in colon motility and sensory response in the GIT. It has been suggested that it may be involved in the IBS-C patient picture of bloating and pain. CCK regulates motor activity: gallbladder contraction and slower transit time (TT). The inhibitory effect of CCK on TT occurs in the ascending colon only. Receptors are in the longitudinal muscle of the colon, enteric nervous system, CNS and particularly mesenteric plexus. CCK acts on neurons and smooth muscle directly and its receptors are involved in pain perception. Hypersensitivity or exaggerated release of CCK increases with IBS symptoms (Varga 2004).

The role of CCK is not well understood in IBS however the possibility of patients having altered release has prompted a number of studies. Sjolund (1996) noted that IBS patients have a more prolonged release of CCK in a human controlled study however no other conclusions were extrapolated. A randomised double blind study of 36 patients trialling a CCK antagonist for IBS-C was not effective in increasing TT (Cremonini 2005). This study was on the effectiveness of a drug and not on the intricacies of CCK activity.


Oxytocin is secreted in response to CCK release and it has increased the pain threshold in rat studies and visceral pain in IBS patients. Lower plasma levels of oxytocin have been reported in IBS and a study into the effect of administration on chronically constipated patients was undertaken in 2005 by Ohlsson et al. It had been demonstrated previously that intravenous oxytocin was effective in improving colonic motility, however this study involved nasal administration which was not significantly effective in increasing colon motility. It did however have a positive impact on depressed mood, abdominal pain and feelings of discomfort (Ohlsson 2005).

Substance P--neuropeptide

In a study of interstitial cystitis and IBS occurring simultaneously in women, elevated levels of substance P and increased mast cell counts of three times the norm were observed (Pang 1996). In this study mast cells were mostly concentrated around nerve endings. In another study by the same author on interstitial cystitis, substance P has been shown to initiate mast cell secretion (Pang 1995, 1996). It is theorised that substance P and the pain of IBS are related (Bischoff 2004, Pang 1996). This has also been suspected by other researchers to have a role in gut hypersensitivity (Guilarte 2006, Santos 2005, Delvaux 2002, Dong 2003). Pang also noted that estradial enhances mast cell secretion by substance P in the bladder and that it may have a similar mechanism in the female colon. This may explain why women have more hypersensitivity generally in IBS. A study on calcium channel blockers for the treatment of IBS (Lu 2000) did not confirm that substance P or neuropeptide Y had any effect on IBS pathology. This might be an area of further study.

Mast cells and inflammation

Mast cells initiate stress induced mucosal inflammation of the colon. They have a role in inflammation, leucocyte activation, antigen identification, phagocytosis and epithelial/vascular permeability. Intestinal mast cells have been affected by neuropeptides such as Substance P in animal studies and their close proximity to nerve endings has made them suspected instigators of IBS symptoms such as pain and hypersensitivity (Bischoff 2004, O'Sullivan 2000, Saavedra 2005).

There is an increase of mast cell mediators due to presence of allergens, resulting in increased water secretion and increased epithelial permeability to albumin, thought to be responsible for abdominal symptoms in IBS (Saavedra 2005).

Mast cells may sensitise enteric nerve endings making them more susceptible to histamine and tryptase. Their role in colon hypersensitivity has been linked to mast cells adjacent to nerve endings (Santos 2004, Delvaux 2002, Guilarte 2006). Saavedra (2005) observed in a controlled in vivo trial that chronic intestinal dysfunction in rats coexists with an increased mast cell count. Rats were exposed to food allergens which resulted in allergic sensitisation and the changes in mast cells were noted. He believes that motility alterations could be related to over excited mast cells rather than an increase in mast cells.

However in the first human trial (in vitro) Bischoff (2004) found that human mast cells did not produce histamine, sulphidoleukotrines or tumor necrosis factor (mediators) after the application of substance P even at different concentrations. In the same study it was found that mast cells previously sensitised by an allergen or type I hypersensitivity reaction did have an increase in meditator production. This finding is in line with that of other examiners (Santos 2005, Delvaux 2002, O'Sullivan 2000, Saavedra 2005). The study by Bischoff was well conducted but involved in vitro human tissue and may not have shown the activity of in vivo mechanisms. He makes the point that in vivo tissue may activate mast cells.

Spiller et al (2000) recorded no significant increase in mast cells post an acute infection of Campylobacter enteritis, in fact some mast cell numbers were reduced in some patients.

A study by O'Sullivan (2000) confirmed that IBS patients have increased numbers of MC. They studied the impact of inflammatory inducers such as stress and infection and found no other identifier of inflammation (lymphocytes, neutrophils, macrophages or plasma cells) other than increased MC count. O'Sullivan makes an interesting theory that IBS may be a systemic condition involving the mast cells. Increases in mast cell numbers in the bladder and airway have been reported in IBS patients (Pang 1995, O'Sullivan 2000).

Wang et al (2004) observed that patients developed IBS symptoms sometimes months after an acute GIT episode. Interleukin-1 (cytokine secreted by macrophages) remained active in excessive amounts in the rectal tissue of patients up to three months after an acute GIT episode. This prolonged response to stress in the GIT was also observed by Spiller (2000). He considers that T lymphocytes may have a role in neuromuscular function by mediating changes and that alterations in the colorectal mucosa can lead to persistent, inflammatory and enteroendocrine dysfunction post infection.

Rectal hypersensitivity

Abnormal bowel patterns and heightened bowel sensitivity are common in IBS patients (Chang 2006, Xiao 2004, Gutherie 2004, Rutkowska 2006, Vege 2004). Visceral or colorectal hypersensitivity may be a marker of IBS (Dong 2004). Whilst pain is often a co-symptom of altered TT and hypersensitivity, it is unclear whether pain is associated with altered TT or sensory hypersensitivity.

IBS patients show a higher degree of self analysis of bowel symptoms and in some cases a preoccupation with their disorder (Gutherie 2004, Vege 2004). In dilation studies patients evaluate their own level of discomfort and this may not be the most appropriate or consistent indicator. In these studies it has been shown that IBS patients perceived alterations in bowel functions even when intestinal motility was normal (Mulak 2006). It is difficult to assess subject perceptions.

Distension studies have been successful in evaluating the effects of patent drugs or bowel tone. In a study by Mulak (2005) a sumatripan 5-HT agonist injection was effective in reducing anal threshold sensation, and the use of balloon distension test was imperative in gaining clinical outcomes.

Studies by Xiao (2004) and Chang (2006) also used distension balloons to evaluate hypersensitivity and pain in IBS and found females had a significantly greater occurrence of both. Here the subjectivity of the patient may have influenced the outcome. It has been found the IBS-C patients do not have the same hypersensitivity to rectal distension nor do males compared with females (Xiao 2004).

Rectal and visceral hypersensitivity is poorly understood. Links have been theorised to prior intestinal infection which may create an environment of low grade inflammation where mast cell secretions can sensitise nerve endings (Spiller 2000, Wang 2004). It has been shown that mast cells are increased in IBS and concentrate at nerve endings in human and rat biopsies (Pang 1996, Dong 2003, O'Sullivan 2000, Saavedra 2005).

Furthermore it has been shown in one rat study that it is the degranulation rate of mast cells that is of significance (Lu 2000).

It could be via mast cell activation that the mechanism of pain of IBS is initiated rather than lumenal distension. Mulak (2006) reported increased anal threshold to pressure but not significant reduction in pain during a drug trial of a 5-HT agonist, indicating that reduced anal resting pressure did not alter the level of pain.

Gender differences in IBS

Physiological and psychological factors have been suggested to explain the higher incidence of IBS in women, although it is uncertain what these might be. The impact of female hormones, particularly in the follicular phase, on GIT hormones and anorectal sensitivity has been referred to but not fully investigated. There are drugs for IBS-D which are specifically efficacious for females (Bush 2001, Kermod-Scott 2000).

Originally it was thought there was no alteration in motor activity for male and female colon tissue, however through the development of IBS drugs these differences have been illustrated. Even though much of the research is on rat colon tissue, it has been observed in the trial of drugs on humans that women have selective efficacy for the 5-HT antagonist alosetron (Chang 2006, Bush 2001, Nozu 2006).

In the study of female mouse tissue, alosetron reduced motor activity 100 times more than that of male tissue (Bush 2001).

It is as a result of this evidence that females may have distribution of receptors vastly different from Sensitivity is one factor that is predominant in women and this is often measured in terms of a lowered threshold to rectal distension with a higher incidence of pain, discomfort and diarrhea (Xiao 2004).

Emerging concepts

IBS often occurs alongside other symptoms such as migraine, headache, lumbago, dysuria, insomnia, chronic fatigue syndrome, fibromyalgia, anxiety, chronic stress and depression (Mulak 2006, Moura 2005, Mu 2006). There may be a link between these symptoms and those of IBS and the role of serotonin in the GIT (Mulak 2006, Crowell 2004). A study showed that serotonin activity was normal on the CNS of IBS patients (Gorard 1996).

The mast cell connection suggests a systemic disorder where there are increases in the number of mast cells in other tissues also (O'Sullivan 2000). Hypersensitivity reaction instigates mast cell activity and its effect in other tissues may have a diagnostic application (Pang 1996, O'Sullivan 2000). The overlap of fibromyalgia, IBS and depression has also been made with regards to low levels of oxytocin. Whilst these disorders do occur individually they have a similarly neurological deficit.


In this review there is evidence to suggest there is local hormone activity of 5-HT. It is of particular significance in IBS-D where it has been shown to be excitatory, increasing the symptoms of increased motility. Research is limited to the design of drugs to antagonise the action of 5-HT. Mast cell activity remains a contentious issue. Most studies show an increase in the number of mast cells in the ileum, some show no changes at all.

There is however enough evidence to support the hypothesis that they have an effect on pain perception and hypersensitivity of the colon. Mast cells may also have a role in the maintenance of persistent immune response and low grade inflammation as demonstrated by post infective studies.

Allergenic response has been shown to increase T cells, enteroendocrine cells and mast cell secretions which may have a role in post infective IBS, food intolerances or chronic stress.

Animal studies, whilst they were well conducted, focused on in vitro tissue as did many of the human trials on neurotransmitters. Living organisms react differently to in vitro tissue due to the interplay of other hormones. Interpretation of animal studies must be done with great care. Research into 5-HT has recently found human specific receptors in the colon and this highlights the obvious fact that comparisons cannot be too heavily drawn between laboratory animals and humans. Human testing is required in the area of the immunological impact on neurotransmitter activity in the dysfunctional colon.

The sample sizes for studies were small, and in only one case histology was conducted over one year. It would be necessary to evaluate neurotransmitter activity over longer time periods of time in the case of post allergic responses and chronic stress.


Aggarwal V, Mc Beth J, Zakrzekska J, Lunt M, Mac Farlane G. 2006. Epidemiology of chronic syndromes that are frequently unexplained; do they have common associated factors? Int J Epip 35;468-76.

Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, Sung J. 2006. Effectiveness in the Chinese herbal formula tongXie Yao Fang for irritable bowel syndrome; a systematic review. JACM 12;401-7.

Bischoff S, Schwengberg S, Lorentz A, Manns M, Bektas H, Sann H, Levi-Schaffer F, Shanahan F, Schemann M. 2004. Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroent Motil 16;185-93.

Borman R, Tilford N, Harmer D, Day N, Ellis E, Sheldrick R, Karey J, Coleman R, Baxter G. 2002. 5-HT 2b receptors play a key role in mediating the excitatory of 5-HT in human colon. Brit J Pharm 135;1144-51.

Braun L, Cohen M. 2005. Herbs & Natural Supplements. Australia: Elsevier.

Brettman L. 2005. Clinical Studies; Dynogen initiates phase II DDP733 trial for patients with IBS-D. Gastroenterology Week Oct 31;32.

Bundy R, Walker A, Middleton R, Marrarkis G, Booth J. 2004. Artichoke leaf extract reduced symptoms of irritable bowel syndrome and improves quality of life in otherwise healthy volunteers suffering from concomitent dyspepsia; a subset analysis. JACM 10;667-9.

Bundy R, Walker A, Richard W, Middleton W, Booth J. 2004. Turmeric Extract may improve ittirable bowel syndrome symptomology in otherwise healthy adults; a pilot study. JACM 6;1015-18.

Bush T, Spencer N, Watters N, Sanders K, Smith T. 2001. Effects of Alosetron on spontaneous migrating motor complexes in murine small and large bowels in vitro. Am J Physiol Gastrointest Liver Physiol 281;974-83.

Chang L. 2006. Irritable bowel syndrome; gender influences sensitivity to rectosigmoid distension in IBS. Womens Health Weekly 9 Sep.

Cilansetron 5-HT 3 serotonin antagonist. 2005. Drugs 6;169-73.

Cremonini F, Camilleri M, McKinzie S, Carlson P, Camilleri C, Burton D, Thomforde G, Urrutia R, Zinzmeister A. 2005. Effect of CCK-1 antagonist, dexloxiglumide in female patients with IBS; a pharmacodynamic and pharmacogenomic study. Am J gastroenterol 100;652-3.

Crowell M. 2004. Role of serotonin in the pathophysiology of the irritable bowel syndrome. British J Pharm 141;1285-93.

Delvaux M. 2002. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. GUT 51;67-71.

Dong W, Zou D, Lei Z, Zou X, Zhu A, Xu G, Yin N, Gong Y, Sun Z, Man X. 2004. Study of Visceral hypersensitivity in irritable bowel sydrome. Chinese J Dig Disease 5;103.

Dong W, Li Z, Zou D, Xu G, Zou X. Zhu A, Yin N, Gong Y. 2003. The changes of mucosal mast cells and substance P in patients with Irritable bowel syndrome. Zhonghua Nei Ke Za Zhi;42;611-14.

Gorard D, Dewsnap P, Medbak S, Perry L, Libby G, Farthing M. 1996. Central 5-HT function in irritable bowel syndrome. Scand J Gastro 10;994-9.

Guilarte M, Santos J, Torres I, Alonso C, Vicario M, Ramos L, Martinez C, Casellas F, Sarperas E, Malagelada J. 2006. Diarrhoea-Predominant IBS patients show mast cell activation and hyperplasia in the jejunum. GUT [Epub ahead of Print].

Gutherie E, Barlow J, Fernandes L, Ratcliffe J, Read N, Thompson D, Tomenson B, Creed F. 2004. The changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome. Psychosomatic Medicine 66;578-82.

Hicks G, Coldwell J, Schindler M, Ward P, Jenkins D, Lynn P, Humphery P, Blackshaw L. 2002. Excitaton of rat colonic afferent fibres by 5-HT (3) receptors. J Physiol 1;861-9.

Kermod-Scott B. 2000. New drug relieves IBS symptoms in women; researchers excited about type III serotonin receptor. Medical Post 36;39.

Koloski N, Boyce P, Talley N. 2005. Is health care seeking for IBS and FD a socially learned response to illness. Dig Dis & Sci 50;158-61.

Konturek P, Konturek S. 2003. The history of gastrointestinal hormones and the Polish contribution to elucidation of their biology and relation to nervous system. J Phy & Pharm 54;83-98.

La J, Kim T, Sung T, Kim H, Kim J, Y I. 2004. Role of mucosal mast cells in visceral hypersensitivity in a rat model of IBS. J Vet Science Korea 5;319-24.

Lu C, Chen C, Chang F, Chang S, Kang L, Lu R, Lee S. 2000. Effect of a calcium channel blocker and antispasmodic in IBS-D. J Gastroenterol Hepatol 15;925-30.

Lubiprostone-Osmotic laxative for IBS-C. 2005. Drugs 6;245-8.

Moura R. 2005. Irritable bowel syndrome. Medicine & Health Rhode Island. 88;342-5.

Mu Z, Huang Y, Zhao B, Liu Z, Zhang B, Wang Q. 2006. Effects of explosive noise on gastrointestinal transit and plasma levels of polypeptide hormones. World J Gastroenterol 14;2280-7.

Mulak A, Paradowski L. 2006. Effect of 5-HT agonist (sumatriptan) on anorectal function in IBS patients. World J Gastroentrol 14;1590-6.

Nozu T, Kudaria M. 2006. Corticotropin-releasing factor induces rectal hypersentisitivity after repetitive painful rectal distension in healthy humans. J Gastro 41;740.

Ohlsson B, Truedsson M, Bangtsson M, Torstenson R, Sjolound K, Bjornsson S, Simren M. 2005. Effects of long term treatment with oxytocin in chronic constipation; a double blind, placebo controlled pilot trial. Neurogastroentrol Motil 17;697-704.

O'Sullivan M, Clayton N, Breslin N, Harman I, Bountra C, Mc Claren A, O'Morain C. 2000. Increased mast cells in the IBS. Neurogastroentrol Motil 12;449-57.

Pang X, Boucher W, Triadafilopoulos G, Sant G, Theoharides T. 1996. Mast cell and substance P-positive nerve involvement with both irritable bowel syndrome and interstitial cystitis. Urology 47;436-8.

Pang X, Marchand J, Sant G, Kream R, Theoharides T. 1995. Increased number of substance P nerve fibres in interstitial cystitis. Brit J Urol 75;744.

Pimentel M, Kong Y, Park S. 2004. IBS subjects with methane on Lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis & Sci 9;84-7.

Rutkowska D, Piaatek J, Tokura H, Linke K, Takasu N, Inatsugi N, Torlinska T. 2006. The influence of the two light intensities during the daytime on the colon motility in patient with IBS; a preliminary report. Biological Rhythm Research 37;241-6.

Saavedra Y, Vergara P. 2005. Hypersensitivity to ovalbumin induced chronic intestinal dysmaturity and increases the number of intestinal mast cells. Neurogastroentrol Motil 17;112-22.

Santos J, Guilarte M, Alsonso C, Malagelada J. 2005. Pathogenesis of irritable bowel syndrome; The mast cell connection. Scand J Gasto 40;129-40.

Scott I, Perry C. 1999. Tegaserod. Drugs 53;491-6.

Sjolund K, Ekman R, Lindgren S, Rehfeld J. 1996. Disturbed motilin and cholecystokinin release in the IBS. Scand J Gastroenterol 31;1110-14.

Spiller R, Jenkins D, Thornley J, Hebden J, Wright T, Skinner M, Neal K. 2000. Increased rectal mucosal enter endocrine cells, T lymphocytes, increased gut permeability following acute Campylobacter enteritis and in post enteritis. GUT 47;804-11.

Tack J, Broekaert D, Fischler B, Oudenhove L, Gevers A, Janssens J. 2006. Controlled crossover study of the selective serotonin reuptake inhibitor Citaloptan in IBS. GUT 55;1095-103.

Talley N. 2001. Serotoninergic neuroenteric modulators. Lancet 358;2061-8.

Theravance. 2006. Clinical trials; Phase I studies, results with agonist for GT motility dysfunction show prokinetic effect. Gastroenterol Weekly 32.

Tortora G, Grabowski S. 2003. Principles of Anatomy & Physiology. USA: Wiley.

Varga G, Balint A, Burghardt B, D'Amato M. 2004. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. British J Pharm 141;1275-84.

Vege S, Locke G, Weaver A, Farmer S, Melton L, Talley N. 2004. Functional gastrointestinal disorders among people with sleep disturbances; a population based study. Mayo Clinic Proc 79;1501-6.

Wang L, Fang X, Pang G. 2004. Bacillary Dysentery as a causative factor of IBS and its pathogenesis. GUT 53;1096-101.

Xiao W, Liu Y. 2004. Rectal hypersensitivity reduced by acupoint TENS in patients with diarrhoea-predominant irritable bowel syndrome; a pilot study. Dig Dis & Sciences 49;312.

Sonia Washburn DBM

Table 1
Research on human and animal studies summarising neurotransmitter
activity in the colorectal mucosa

Topic Reference Design

Effect of methane on Pimentel Human, blind
5-HT release (full) 2004

Altered CCK, motilin Sjolund Const, study,
in IBS (abstract) 1996 human

Effect of SSRI in Tack 2006 DBP crossover
IBS symptoms human

5-HT agonist drug Thervance DBPC phase I
test (abstract) 2006 human

Effect of auditory Mu 2006 In vivo rodent
stress on GIT
hormones (full)

Ca channel blocker Lu 2000 RB human
in IBS-D (abstract)

CCK antagonists for Cremonini RBP human
IBS females 2005

Function of 5-HT in Gorara 1995 Unblind open
CNS of IBS patients label human

Alosetron, 5-HT Bush 2001 In vivo rodent
antagonist in IBS drug trial
:gender specific
responses (full)

Light impact on Rutkowska Open
biorhythm of IBS 2006 experimental
patients (abstract)

5-HT agonist in IBS Malak 2005 RB PC
rectal function (full) crossover

Rectal Xiao 2004 Open pilot
hypersensitivity in semi blind
IBS (full)

Functional GI Vege 2004 Population
disorders and sleep study
disturbances (full)

Rat colonic afferent Hicks 2002 In vivo rodent
fibres have 5-HT
receptors (full)

Psychological state Guthrie RCT
and rectal threshold 2004 Human
in IBS (full)

5-HT agonist for Nurbhai Phase I RBPC
IBS-C (abstract) 2005 Human

Women have an Chang 2006 R human

Mast cell, Substance Pang 1996 human
P in IBS (abstract)

Post-dysenteric IBS Spiller 2000 CT
and increased
mucosal cells, T
cells, gut
permeability (full)

5-HT excites human Borman Human tissue
colon tissue 2002

Sensitising to food Saavedra Rat. CP
allergies and effects 2004
on mast cells (full)

Neuropeptides in Bischoff Human
human tissue as 2004
mediators of mast
cells (full)

Increased mast cells O'Sullivan Human biopsy
in IBS (full) 2000

Oxytocin in chronic Ohlsson RDBPC
constipation (full) 2004 Human

Mast cells and Dong 2003 Human biopsy
substance P in IBS

IBS-C have mast cell Guilante Human biopsy
activation (abstract) 2006

Mast cells in IBS and La 2004 Rodent

Visceral Dong 2004 Human
hypersensitivity in
IBS (abstract)

Bacillary Dysentery Wang 2004 Cohort
as a causative factor
in IBS (full)

Topic Sample Evidence

Effect of methane on 18 ++
5-HT release (full)

Altered CCK, motilin 29 ++
in IBS (abstract)

Effect of SSRI in 23 +
IBS symptoms

5-HT agonist drug 41 +
test (abstract)

Effect of auditory 64 ++
stress on GIT
hormones (full)

Ca channel blocker 91 +/-
in IBS-D (abstract)

CCK antagonists for 36 -
IBS females

Function of 5-HT in 39 -
CNS of IBS patients

Alosetron, 5-HT tissue ++
antagonist in IBS
:gender specific
responses (full)

Light impact on 8 ++
biorhythm of IBS
patients (abstract)

5-HT agonist in IBS 22 ++
rectal function (full)

Rectal 30
hypersensitivity in
IBS (full)

Functional GI 2269 +
disorders and sleep
disturbances (full)

Rat colonic afferent tissue ++
fibres have 5-HT
receptors (full)

Psychological state 257 +
and rectal threshold
in IBS (full)

5-HT agonist for
IBS-C (abstract)

Women have an 84 +

Mast cell, Substance Tissue ++
P in IBS (abstract) biopsy

Post-dysenteric IBS 31 +
and increased
mucosal cells, T
cells, gut
permeability (full)

5-HT excites human Tissue ++
colon tissue

Sensitising to food 59 ++
allergies and effects
on mast cells (full)

Neuropeptides in Tissue -/+
human tissue as
mediators of mast
cells (full)

Increased mast cells Tissue +
in IBS (full)

Oxytocin in chronic 49 --
constipation (full)

Mast cells and 67 ++
substance P in IBS

IBS-C have mast cell 34 +
activation (abstract)

Mast cells in IBS and +/-

Visceral 63 +
hypersensitivity in
IBS (abstract)

Bacillary Dysentery 295 +
as a causative factor
in IBS (full)

Topic Outcomes

Effect of methane on Methane link to constipation
5-HT release (full) via serum 5-HT levels

Altered CCK, motilin Fats > and prolong CCK
in IBS (abstract) release in IBS

Effect of SSRI in SSRI improved pain, bloat
IBS symptoms compared to placebo

5-HT agonist drug 5-HT agonist mildly improved
test (abstract) colon motility in healthy

Effect of auditory Explosive/loud noise =
stress on GIT stress=altered gut hormone
hormones (full) secretion and transit time

Ca channel blocker Substance P and neuropeptide
in IBS-D (abstract) Y are not significant in the
 pathogenesis of IBS

CCK antagonists for CCK antagonist did not alter
IBS females TT overall

Function of 5-HT in CNS 5-HT pathways are
CNS of IBS patients normal in IBS

Alosetron, 5-HT Female specific efficacy of
antagonist in IBS drug. Maybe due to receptor
:gender specific distribution in ileum
responses (full)

Light impact on Intense light improved IBS-D
biorhythm of IBS and IBS-C symptoms
patients (abstract)

5-HT agonist in IBS Drug reduced visceral
rectal function (full) hypersensitivity

Rectal A reduced sensory threshold
hypersensitivity in exists in IBS-D and females:
IBS (full) males

Functional GI IBS-D and sleep disturbances
disorders and sleep occur simultaneously with
disturbances (full) significance

Rat colonic afferent Colonic spinal nerves have 5-
fibres have 5-HT HT receptors. Role
receptors (full) undetermined

Psychological state Sexual abuse/anxiety/
and rectal threshold depression leads to lower
in IBS (full) rectal threshold

5-HT agonist for Established drug efficacy and
IBS-C (abstract) tolerance

Women have an Women have a perceived
increased sensitivity with distension

Mast cell, Substance IBS patients have increased
P in IBS (abstract) mast cell population and
 increased substance P at nerve

Post-dysenteric IBS Acute GIT episode can result
and increased in low grade inflammation of
mucosal cells, T up to one year. Increased 5-HT
cells, gut in IBS
permeability (full)

5-HT excites human Increased colon 5-HT 2B
colon tissue receptors--human specific
 Undetermined mechanism for
 5-HT. Possible direct effect on
 smooth muscle

Sensitising to food Chronic intestinal dysfunction
allergies and effects coexists with increased mast
on mast cells (full) cells. Unconfirmed role of
 CCK on colon motility

Neuropeptides in No release of histamine by
human tissue as Sub P. Preactivated cells (via
mediators of mast IgE) receptor did increase
cells (full) mediator release

Increased mast cells Mast cells significantly in
in IBS (full) crease in the ileocecum in IBS

Oxytocin in chronic Oxytocin did not improve
constipation (full) colon motility, possibly due to
 nasal administration

Mast cells and Increased mast cells at
substance P in IBS ileocecal junction in IBS

IBS-C have mast cell Stress induces mast cell
activation (abstract) activity

Mast cells in IBS and Mast cells were not
visceral influenced.
hypersensitivity Degranulation rate of mast
(abstract) cells in IBS is increased

Visceral Visceral hypersensitivity is a
hypersensitivity in marker of IBS
IBS (abstract)

Bacillary Dysentery Immune and nervous systems
as a causative factor play a significant role in IBS
in IBS (full) pathology
COPYRIGHT 2007 National Herbalists Association of Australia
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Under grad; Irritable bowel syndrome
Author:Washburn, Sonia
Publication:Australian Journal of Medical Herbalism
Geographic Code:8AUST
Date:Dec 22, 2007
Previous Article:Linnaeus turns 300.
Next Article:Enhanced antioxidant effect of a herbal-nutrient complex including ascorbic acid and Polygonum cuspidatum extract (containing resveratrol).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters